Coherus Biosciences | CHRS - Kewajiban Lancar





Kewajiban Lancar Perubahan Tanggal
AbbVie USD 43.29B 3.9B 2025-12
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Akebia Therapeutics USD 162.94M 29.56M 2025-12
ALKERMES USD 543.44M 69.08M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amarin USD 194.46M 12.23M 2025-12
Amgen USD 25.49B 3.7B 2025-12
Baxter International USD 2.97B 805M 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Coherus Biosciences USD 140.39M 231.91M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Fujifilm JPY 1.2T 44.21B 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
Ironwood Pharmaceuticals USD 242.5M 9.98M 2025-09
Merck USD 28.63B 2.59B 2025-09
Myriad Genetics USD 133.8M 14.2M 2025-12
Pacira USD 120.59M 13.51M 2025-12
Perrigo USD 1.01B 132.4M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Teva Pharmaceutical Industries USD 13.46B 1.96B 2025-12
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12
Xencor USD 95.91M 9.42M 2025-12
Zoetis USD 2.24B 428M 2025-12